BXN Stock Overview
A life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Bioxyne Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.021 |
| 52 Week Low | AU$0.004 |
| Beta | 0.78 |
| 11 Month Change | -7.14% |
| 3 Month Change | 8.33% |
| 1 Year Change | 8.33% |
| 33 Year Change | -31.58% |
| 5 Year Change | -18.75% |
| Change since IPO | -93.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXN | AU Personal Products | AU Market | |
|---|---|---|---|
| 7D | 8.3% | -7.9% | 0.9% |
| 1Y | 8.3% | 54.5% | 17.7% |
Return vs Industry: BXN underperformed the Australian Personal Products industry which returned 54.5% over the past year.
Return vs Market: BXN underperformed the Australian Market which returned 17.7% over the past year.
Price Volatility
| BXN volatility | |
|---|---|
| BXN Average Weekly Movement | 30.0% |
| Personal Products Industry Average Movement | 5.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: BXN's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BXN's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Sam Watson | bioxyne.com |
Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products.
Bioxyne Limited Fundamentals Summary
| BXN fundamental statistics | |
|---|---|
| Market cap | AU$26.61m |
| Earnings (TTM) | -AU$12.80m |
| Revenue (TTM) | AU$9.64m |
2.8x
P/S Ratio-2.1x
P/E RatioIs BXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXN income statement (TTM) | |
|---|---|
| Revenue | AU$9.64m |
| Cost of Revenue | AU$5.93m |
| Gross Profit | AU$3.72m |
| Other Expenses | AU$16.51m |
| Earnings | -AU$12.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0063 |
| Gross Margin | 38.53% |
| Net Profit Margin | -132.73% |
| Debt/Equity Ratio | 1.1% |
How did BXN perform over the long term?
See historical performance and comparison